Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Bajetta

Showing results (151-160 of 178) with videos related to

Pageof 18
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 12, 2002
Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumoursE Bajetta, L Ferrari, G Procopio, et al.
The Journal of Steroid Biochemistry and Molecular Biology|May 2, 2002
Short-term effects of anastrozole treatment on insulin-like growth factor system in postmenopausal advanced breast cancer patientsL Ferrari, A Martinetti, N Zilembo, et al.
Lancet (London, England)|November 10, 1998
Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancerP Rougier, E Van Cutsem, E Bajetta, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 16, 2014
Activity and safety of RAD001 (everolimus) in patients affected by biliary tract cancer progressing after prior chemotherapy: a phase II ITMO studyR Buzzoni, S Pusceddu, E Bajetta, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 12, 2002
Adjuvant chemotherapy in gastric cancer: 5-year results of a randomised study by the Italian Trials in Medical Oncology (ITMO) GroupE Bajetta, R Buzzoni, L Mariani, et al.
Acta Oncologica (Stockholm, Sweden)|January 1, 1993
Treatment of carcinoid syndrome with recombinant interferon alpha-2aM Di Bartolomeo, E Bajetta, N Zilembo, et al.
European Journal of Cancer (Oxford, England : 1990)|April 1, 1997
The minimal effective exemestane dose for endocrine activity in advanced breast cancerE Bajetta, N Zilembo, C Noberasco, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 14, 2006
Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-alpha2b in metastatic melanomaE Bajetta, M Del Vecchio, P Nova, et al.
Targeted Oncology|July 4, 2013
Lack of KRAS, NRAS, BRAF and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFTM Di Bartolomeo, F Pietrantonio, F Perrone, et al.
Breast (Edinburgh, Scotland)|February 18, 2004
c-erbB 2 serum level as prognostic factor in hormonally treated advanced breast cancer patientsN Zilembo, L Mariani, A Martinetti, et al.
Pageof 18

Showing results (151-160 of 178) with videos related to

Sort By:
Pageof 18
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 12, 2002
Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumoursE Bajetta, L Ferrari, G Procopio, et al.
The Journal of Steroid Biochemistry and Molecular Biology|May 2, 2002
Short-term effects of anastrozole treatment on insulin-like growth factor system in postmenopausal advanced breast cancer patientsL Ferrari, A Martinetti, N Zilembo, et al.
Lancet (London, England)|November 10, 1998
Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancerP Rougier, E Van Cutsem, E Bajetta, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 16, 2014
Activity and safety of RAD001 (everolimus) in patients affected by biliary tract cancer progressing after prior chemotherapy: a phase II ITMO studyR Buzzoni, S Pusceddu, E Bajetta, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 12, 2002
Adjuvant chemotherapy in gastric cancer: 5-year results of a randomised study by the Italian Trials in Medical Oncology (ITMO) GroupE Bajetta, R Buzzoni, L Mariani, et al.
Acta Oncologica (Stockholm, Sweden)|January 1, 1993
Treatment of carcinoid syndrome with recombinant interferon alpha-2aM Di Bartolomeo, E Bajetta, N Zilembo, et al.
European Journal of Cancer (Oxford, England : 1990)|April 1, 1997
The minimal effective exemestane dose for endocrine activity in advanced breast cancerE Bajetta, N Zilembo, C Noberasco, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 14, 2006
Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-alpha2b in metastatic melanomaE Bajetta, M Del Vecchio, P Nova, et al.
Targeted Oncology|July 4, 2013
Lack of KRAS, NRAS, BRAF and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFTM Di Bartolomeo, F Pietrantonio, F Perrone, et al.
Breast (Edinburgh, Scotland)|February 18, 2004
c-erbB 2 serum level as prognostic factor in hormonally treated advanced breast cancer patientsN Zilembo, L Mariani, A Martinetti, et al.
Pageof 18